SVB Wealth LLC Invests $555,000 in Roche Holding AG (OTCMKTS:RHHBY)

SVB Wealth LLC acquired a new position in Roche Holding AG (OTCMKTS:RHHBY) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 15,904 shares of the company’s stock, valued at approximately $555,000.

Other hedge funds also recently made changes to their positions in the company. Brooklyn Investment Group acquired a new stake in shares of Roche during the third quarter worth $40,000. IHT Wealth Management LLC acquired a new stake in shares of Roche during the third quarter worth $236,000. Verity Asset Management Inc. acquired a new position in Roche in the 3rd quarter worth approximately $253,000. Canopy Partners LLC grew its position in Roche by 4.6% during the 3rd quarter. Canopy Partners LLC now owns 7,772 shares of the company’s stock worth $310,000 after purchasing an additional 344 shares in the last quarter. Finally, Confluence Investment Management LLC grew its position in Roche by 26.3% during the 4th quarter. Confluence Investment Management LLC now owns 13,981 shares of the company’s stock worth $488,000 after purchasing an additional 2,910 shares in the last quarter.

Roche Stock Up 0.2 %

OTCMKTS RHHBY opened at $41.83 on Tuesday. Roche Holding AG has a 1-year low of $29.20 and a 1-year high of $42.43. The company has a quick ratio of 0.97, a current ratio of 1.26 and a debt-to-equity ratio of 0.86. The firm’s fifty day simple moving average is $38.38 and its 200-day simple moving average is $38.41.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Morgan Stanley initiated coverage on Roche in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. UBS Group upgraded Roche from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, Sanford C. Bernstein raised Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.